Schistosomiasis  ||| S:0 E:16 ||| FW
associated  ||| S:16 E:27 ||| FW
pulmonary  ||| S:27 E:37 ||| FW
hypertension  ||| S:37 E:50 ||| FW
Schistosomiasis  ||| S:50 E:66 ||| NNP
is  ||| S:66 E:69 ||| VBZ
one  ||| S:69 E:73 ||| CD
of  ||| S:73 E:76 ||| IN
the  ||| S:76 E:80 ||| DT
most  ||| S:80 E:85 ||| RBS
prevalent  ||| S:85 E:95 ||| JJ
infectious  ||| S:95 E:106 ||| JJ
diseases ||| S:106 E:114 ||| NNS
,  ||| S:114 E:116 ||| ,
endemic  ||| S:116 E:124 ||| VBG
in  ||| S:124 E:127 ||| IN
more  ||| S:127 E:132 ||| JJR
than  ||| S:132 E:137 ||| IN
70  ||| S:137 E:140 ||| CD
countries ||| S:140 E:149 ||| NNS
,  ||| S:149 E:151 ||| ,
mainly  ||| S:151 E:158 ||| RB
within  ||| S:158 E:165 ||| IN
the  ||| S:165 E:169 ||| DT
developing  ||| S:169 E:180 ||| VBG
world ||| S:180 E:185 ||| NN
.  ||| S:185 E:187 ||| .
More  ||| S:187 E:192 ||| RBR
than  ||| S:192 E:197 ||| IN
200  ||| S:197 E:201 ||| CD
million  ||| S:201 E:209 ||| CD
people  ||| S:209 E:216 ||| NNS
might  ||| S:216 E:222 ||| MD
be  ||| S:222 E:225 ||| VB
infected  ||| S:225 E:234 ||| JJ
worldwide ||| S:234 E:243 ||| NN
;  ||| S:243 E:245 ||| :
about  ||| S:245 E:251 ||| IN
20  ||| S:251 E:254 ||| CD
million  ||| S:254 E:262 ||| CD
of  ||| S:262 E:265 ||| IN
those  ||| S:265 E:271 ||| DT
might  ||| S:271 E:277 ||| MD
develop  ||| S:277 E:285 ||| VB
severe  ||| S:285 E:292 ||| JJ
disease ||| S:292 E:299 ||| NN
.  ||| S:299 E:301 ||| .
The  ||| S:301 E:305 ||| DT
hepatosplenic  ||| S:305 E:319 ||| JJ
form  ||| S:319 E:324 ||| NN
of  ||| S:324 E:327 ||| IN
schistosomiasis  ||| S:327 E:343 ||| NN
is  ||| S:343 E:346 ||| VBZ
the  ||| S:346 E:350 ||| DT
most  ||| S:350 E:355 ||| RBS
prevalent  ||| S:355 E:365 ||| JJ
form  ||| S:365 E:370 ||| NN
of  ||| S:370 E:373 ||| IN
chronic  ||| S:373 E:381 ||| JJ
disease ||| S:381 E:388 ||| NN
,  ||| S:388 E:390 ||| ,
characterised  ||| S:390 E:404 ||| VBG
by  ||| S:404 E:407 ||| IN
the  ||| S:407 E:411 ||| DT
presence  ||| S:411 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
periportal  ||| S:423 E:434 ||| JJ
fibrosis  ||| S:434 E:443 ||| NN
and  ||| S:443 E:447 ||| CC
portal  ||| S:447 E:454 ||| JJ
hypertension ||| S:454 E:466 ||| NN
.  ||| S:466 E:468 ||| .
Pulmonary  ||| S:468 E:478 ||| JJ
hypertension  ||| S:478 E:491 ||| NN
is  ||| S:491 E:494 ||| VBZ
a  ||| S:494 E:496 ||| DT
well-recognised  ||| S:496 E:512 ||| JJ
complication  ||| S:512 E:525 ||| NN
of  ||| S:525 E:528 ||| IN
hepatosplenic  ||| S:528 E:542 ||| JJ
schistosomiasis ||| S:542 E:557 ||| NN
.  ||| S:557 E:559 ||| .
Recent  ||| S:559 E:566 ||| JJ
prevalent  ||| S:566 E:576 ||| JJ
studies  ||| S:576 E:584 ||| NNS
revealed  ||| S:584 E:593 ||| VBD
that  ||| S:593 E:598 ||| DT
schistosomiasis  ||| S:598 E:614 ||| JJ
patients  ||| S:614 E:623 ||| NNS
may  ||| S:623 E:627 ||| MD
develop  ||| S:627 E:635 ||| VB
precapillary  ||| S:635 E:648 ||| NNS
and  ||| S:648 E:652 ||| CC
postcapillary  ||| S:652 E:666 ||| JJ
forms  ||| S:666 E:672 ||| NNS
of  ||| S:672 E:675 ||| IN
pulmonary  ||| S:675 E:685 ||| JJ
hypertension ||| S:685 E:697 ||| NN
,  ||| S:697 E:699 ||| ,
reinforcing  ||| S:699 E:711 ||| VBG
the  ||| S:711 E:715 ||| DT
role  ||| S:715 E:720 ||| NN
of  ||| S:720 E:723 ||| IN
invasive  ||| S:723 E:732 ||| JJ
haemodynamic  ||| S:732 E:745 ||| JJ
measurements  ||| S:745 E:758 ||| NNS
for  ||| S:758 E:762 ||| IN
the  ||| S:762 E:766 ||| DT
proper  ||| S:766 E:773 ||| JJ
diagnosis ||| S:773 E:782 ||| NN
.  ||| S:782 E:784 ||| .
These  ||| S:784 E:790 ||| DT
studies  ||| S:790 E:798 ||| NNS
also  ||| S:798 E:803 ||| RB
demonstrated  ||| S:803 E:816 ||| VBN
that  ||| S:816 E:821 ||| IN
schistosomiasis  ||| S:821 E:837 ||| FW
associated  ||| S:837 E:848 ||| FW
pulmonary  ||| S:848 E:858 ||| FW
arterial  ||| S:858 E:867 ||| FW
hypertension  ||| S:867 E:880 ||| FW
may  ||| S:880 E:884 ||| MD
represent  ||| S:884 E:894 ||| VB
the  ||| S:894 E:898 ||| DT
most  ||| S:898 E:903 ||| RBS
prevalent  ||| S:903 E:913 ||| JJ
form  ||| S:913 E:918 ||| NN
of  ||| S:918 E:921 ||| IN
pulmonary  ||| S:921 E:931 ||| FW
arterial  ||| S:931 E:940 ||| FW
hypertension  ||| S:940 E:953 ||| FW
( ||| S:953 E:954 ||| -LRB-
PAH ||| S:954 E:957 ||| NNP
) ||| S:957 E:958 ||| -RRB-
.  ||| S:958 E:960 ||| .
Many  ||| S:960 E:965 ||| JJ
aspects  ||| S:965 E:973 ||| NNS
regarding  ||| S:973 E:983 ||| VBG
the  ||| S:983 E:987 ||| DT
appropriate  ||| S:987 E:999 ||| JJ
management  ||| S:999 E:1010 ||| NN
of  ||| S:1010 E:1013 ||| IN
Sch-PAH  ||| S:1013 E:1021 ||| JJ
patients  ||| S:1021 E:1030 ||| NNS
still  ||| S:1030 E:1036 ||| RB
remain  ||| S:1036 E:1043 ||| VB
to  ||| S:1043 E:1046 ||| TO
be  ||| S:1046 E:1049 ||| VB
elucidated ||| S:1049 E:1059 ||| NNS
,  ||| S:1059 E:1061 ||| ,
as  ||| S:1061 E:1064 ||| IN
the  ||| S:1064 E:1068 ||| DT
use  ||| S:1068 E:1072 ||| NN
of  ||| S:1072 E:1075 ||| IN
specific  ||| S:1075 E:1084 ||| JJ
PAH  ||| S:1084 E:1088 ||| NNP
therapy ||| S:1088 E:1095 ||| NN
.  ||| S:1095 E:1097 ||| .
Although  ||| S:1097 E:1106 ||| IN
the  ||| S:1106 E:1110 ||| DT
ongoing  ||| S:1110 E:1118 ||| JJ
control  ||| S:1118 E:1126 ||| NN
programmes  ||| S:1126 E:1137 ||| NNS
that  ||| S:1137 E:1142 ||| WDT
started  ||| S:1142 E:1150 ||| VBD
within  ||| S:1150 E:1157 ||| IN
the  ||| S:1157 E:1161 ||| DT
1980s  ||| S:1161 E:1167 ||| NNS
have  ||| S:1167 E:1172 ||| VBP
clearly  ||| S:1172 E:1180 ||| RB
improved  ||| S:1180 E:1189 ||| VBN
the  ||| S:1189 E:1193 ||| DT
schistosomiasis  ||| S:1193 E:1209 ||| JJ
cenario  ||| S:1209 E:1217 ||| JJ
worldwide ||| S:1217 E:1226 ||| NN
,  ||| S:1226 E:1228 ||| ,
Sch-PAH  ||| S:1228 E:1236 ||| NNP
will  ||| S:1236 E:1241 ||| MD
be  ||| S:1241 E:1244 ||| VB
seen  ||| S:1244 E:1249 ||| VBN
for  ||| S:1249 E:1253 ||| IN
decades  ||| S:1253 E:1261 ||| NNS
after  ||| S:1261 E:1267 ||| IN
proper  ||| S:1267 E:1274 ||| JJ
control  ||| S:1274 E:1282 ||| NN
is  ||| S:1282 E:1285 ||| VBZ
reached ||| S:1285 E:1292 ||| VBN
,  ||| S:1292 E:1294 ||| ,
strengthening  ||| S:1294 E:1308 ||| VBG
the  ||| S:1308 E:1312 ||| DT
current  ||| S:1312 E:1320 ||| JJ
need  ||| S:1320 E:1325 ||| NN
for  ||| S:1325 E:1329 ||| IN
comprehensive  ||| S:1329 E:1343 ||| JJ
studies  ||| S:1343 E:1351 ||| NNS
aiming  ||| S:1351 E:1358 ||| VBG
to  ||| S:1358 E:1361 ||| TO
clarify  ||| S:1361 E:1369 ||| VB
the  ||| S:1369 E:1373 ||| DT
multiple  ||| S:1373 E:1382 ||| JJ
mechanisms  ||| S:1382 E:1393 ||| NNS
involved  ||| S:1393 E:1402 ||| VBN
in  ||| S:1402 E:1405 ||| IN
the  ||| S:1405 E:1409 ||| DT
pathophysiology  ||| S:1409 E:1425 ||| NN
of  ||| S:1425 E:1428 ||| IN
this  ||| S:1428 E:1433 ||| DT
particular  ||| S:1433 E:1444 ||| JJ
subgroup  ||| S:1444 E:1453 ||| NN
of  ||| S:1453 E:1456 ||| IN
PAH ||| S:1456 E:1459 ||| NNP
.  ||| S:1459 E:1461 ||| .
